GeneFerm Biotechnology Co Ltd (1796) — Financial Flexibility Index
GeneFerm Biotechnology Co Ltd (1796) has a Financial Flexibility Index of 0.02x as of June 2025. Free cash flow of NT$7.43 Million (operating CF NT$1.45 Million minus capex NT$5.98 Million) represents 0% of total liabilities (NT$453.10 Million). Check 1796 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
GeneFerm Biotechnology Co Ltd Financial Flexibility Index (2017–2024)
Historical Financial Flexibility Index trend for GeneFerm Biotechnology Co Ltd across 8 annual periods. For the full cash flow conversion analysis, see GeneFerm Biotechnology Co Ltd (1796) cash conversion ratio.
Annual Financial Flexibility Index for GeneFerm Biotechnology Co Ltd (2017–2024)
Year-by-year free cash flow to debt coverage for GeneFerm Biotechnology Co Ltd. Explore GeneFerm Biotechnology Co Ltd cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (TWD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.09x | NT$30.79 Million | NT$8.09 Million | NT$358.31 Million | ▼ -90.7% |
| 2023 | 0.93x | NT$261.72 Million | NT$190.31 Million | NT$282.54 Million | ▼ -17.1% |
| 2022 | 1.12x | NT$400.85 Million | NT$122.43 Million | NT$358.86 Million | ▲ +146.6% |
| 2021 | 0.45x | NT$257.84 Million | NT$112.23 Million | NT$569.22 Million | ▲ +91.4% |
| 2020 | 0.24x | NT$138.74 Million | NT$56.42 Million | NT$586.38 Million | ▼ -84.3% |
| 2019 | 1.51x | NT$69.26 Million | NT$14.69 Million | NT$46.00 Million | ▲ +198.6% |
| 2018 | 0.50x | NT$70.94 Million | NT$42.14 Million | NT$140.69 Million | ▼ -15.9% |
| 2017 | 0.60x | NT$116.23 Million | NT$61.08 Million | NT$193.79 Million | — |